Journal Home
Search for

Articles in Press

Return to articles in press list

Peripheral expression of key regulatory kinases in Alzheimer's disease and Parkinson's disease

M.T. Armenteroa1email address, E. Sinforiania2email address, C. Ghezzia1email address, E. Bazzinia1email address, G. Levandisa1email address, G. Ambrosia1email address, R. Zangagliaa3email address, C. Pacchettia3email address, C. Ceredabemail address, E. Covabemail address, E. Bassobemail address, D. Celicemail address, E. Martignonidemail address, G. Nappiaeemail address, F. BlandiniaCorresponding Author Informationemail address

Received 8 June 2009; received in revised form 27 October 2009; accepted 7 January 2010. published online 27 January 2010.
Corrected Proof

Abstract 

Alteration of key regulatory kinases may cause aberrant protein phosphorylation and aggregation in Alzheimer's disease (AD) and Parkinson's disease (PD). In this study, we investigated expression and phosphorylation status of glycogen synthase kinase 3 (GSK-3), protein kinase B (Akt) and tau protein in peripheral blood lymphocytes of 20 AD, 25 PD patients and 20 healthy controls.

GSK-3 was increased in AD and PD patients. In these latter, GSK-3 levels were positively correlated with daily l-Dopa intake. Phosphorylated Akt expression was augmented in both groups; total Akt levels were increased only in AD patients and were positively correlated with disease duration and severity. Total and phosphorylated tau were increased only in AD, with phospho-tau levels being positively correlated with levels of total tau, Akt, and disease duration. No correlations between protein levels and clinical variables were found in PD patients.

Investigation of peripheral changes in the expression of specific kinases may, therefore, lead to the development of innovative biomarkers of neurodegeneration, particularly for AD.

a Interdepartmental Research Center for Parkinson's Disease, IRCCS Neurological Institute “C. Mondino”, Via Mondino 2, 27100 Pavia (PV), Italy

b Laboratory of Experimental Neurobiology, IRCCS Neurological Institute “C. Mondino”, Pavia, Italy

c IRCCS Centro Neurolesi “Bonino-Pulejo”, Messina, Italy

d Dept. of Clinical Medicine, University of Insubria, Varese/Neurorehabilitation and Movement Disorders Unit, IRCCS Fondazione S. Maugeri, Tradate, Italy

e Chair of Neurology, University of Rome “La Sapienza”, Rome, Italy

Corresponding Author InformationCorresponding author. Tel.: +39 0382 380416; fax: +39 0382 380448.

1 Laboratory of Functional Neurochemistry.

2 Alzheimer's Disease Assessment Unit.

3 Center for Parkinson's Disease and Movement Disorders.

PII: S0197-4580(10)00033-3

doi:10.1016/j.neurobiolaging.2010.01.004